Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.
Chem Soc Rev. 2018 Jun 5;47(11):3816-3830. doi: 10.1039/c7cs00220c.
Covalent inhibition is a rapidly growing discipline within drug discovery. Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues. Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small molecule inhibitors have failed. Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small molecule inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target. In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field. We also describe some strategies and computational tools to enable successful covalent drug discovery.
共价抑制是药物发现领域中一个快速发展的学科。许多历史上的共价抑制剂都是偶然发现的,由于潜在的毒性问题,这种作用机制通常被认为是不可取的。最近的进展使得这种观点发生了重大转变,因为共价抑制在那些以前尝试识别非共价小分子抑制剂但失败的靶点上显示出了前景。靶向共价抑制剂(TCIs)可以为药物发现科学家提供增加小分子抑制剂的效力和/或选择性的能力,通过附着设计用于与靶标中的特定位点共价结合的反应性官能团。在本教程综述中,我们介绍了共价抑制的更广泛概念,讨论了这种方法的潜在益处和挑战,并概述了该领域的现状。我们还描述了一些策略和计算工具,以实现成功的共价药物发现。